Clinical utilities of aromatase inhibitors in breast cancer

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to treating breast cancer in both early stage in the adjuvant setting and metastatic disease. This article reviews mechanism of action, AI classification, and clinical utilities of AIs in various clinical settings in the context of breast cancer.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalInternational Journal of Women's Health
StatePublished - May 6 2015


  • Aromatase inhibitor
  • Breast cancer
  • Endocrine therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology
  • Maternity and Midwifery


Dive into the research topics of 'Clinical utilities of aromatase inhibitors in breast cancer'. Together they form a unique fingerprint.

Cite this